In-depth analysis of the critical issues impacting the full spectrum of the pharmaceutical manufacturing value chain.
Driven by increased biologic-based drug development and industry capacity needs, biomanufacturing is an active area of investment for CDMOs/CMOs with several large-scale expansions recently announced or underway. What CDMOs/CMOs are expanding? DCAT...
The Biden Administration has proposed $6.5 billion in funding to establish a new federal agency within the National Institutes of Health to drive bio/pharmaceutical innovation in areas such as cancer, diabetes, Alzheimer’s disease, and other areas...
Viatris, the new company formed from the combination of Mylan and Upjohn, Pfizer’s off-patent branded and generic established medicines business, is proceeding with a $1-billion restructuring initiative, which includes a rationalization of its...
Janet Woodcock, Acting Commissioner of the FDA, provides an update on the FDA’s inspection activity during the COVID-19 pandemic, including what new tools the agency has used for inspections, which has included a mix of mission-critical, on-site...
Congress introduced legislation last week (March 23, 2021) to lower prescription drug pricing in the US. The measures include tying US drug pricing to other industrialized countries, allowing the US government to negotiate drug pricing under...
A newly released DCAT Research & Benchmarking study details how bio/pharmaceutical companies and suppliers are managing business continuity risks resulting from the COVID-19 pandemic and how lessons learned are affecting their approach to...
The need to improve supply-chain resilience in wake of disruptions caused by COVID-19 has caused a re-assessment of supply chains and manufacturing networks. What role will digital tools, such as artificial intelligence, advanced analytics, and...
The European Commission held a kick-off meeting of the structured dialogue process of the EU’s Pharmaceutical Strategy to address ways to improve the resilience of the EU's pharmaceutical manufacturing value chain. High-level representatives from...
What were some of the key capital investments in manufacturing by the pharmaceutical majors globally in 2020 and 2021 to date? Biomanufacturing for both traditional biologics and new modalities, such as cell and gene therapies, continues to be an...
This week (March 15, 2021), the European Council endorsed a new chemicals strategy to set a long-term vision for the European Union’s (EU) chemicals policy. It is asking the European Commission to implement several actions, including streamlining...
